(2) DUTIES.—The interagency technical review 
panel shall serve as a ‘‘shadow’’ panel to the Global 
Fund by—
(A) periodically reviewing all proposals re-
ceived by the Global Fund; and 
(B) providing guidance to the United 
States persons who are representatives on the 
panels, committees, and boards of the Global 
Fund, on the technical efficacy, suitability, and 
appropriateness of the proposals, and ensuring 
that such persons are fully informed of tech-
nical inadequacies or other aspects of the pro-
posals that are inconsistent with the purposes 
of this or any other Act relating to the provi-
sion of foreign assistance in the area of AIDS. 
(3) MEMBERSHIP.—The interagency technical 
review panel shall consist of qualified medical and 
development experts who are officers or employees of 
the Department of Health and Human Services, the 
Department of State, and the United States Agency 
for International Development. 
(4) CHAIR.—The Coordinator referred to in 
paragraph (1) shall chair the interagency technical 
review panel. 
(f) MONITORING BY COMPTROLLER GENERAL.—
(1) MONITORING.—The Comptroller General 
shall monitor and evaluate projects funded by the 
Global Fund. 
(2) REPORT.—The Comptroller General shall 
on a biennial basis shall prepare and submit to the 
appropriate congressional committees a report that 
contains the results of the monitoring and evaluation 
described in paragraph (1) for the preceding 2-year 
period. 
(g) PROVISION OF INFORMATION TO CONGRESS.—
The Coordinator of United States Government Activities 
to Combat HIV/AIDS Globally shall make available to the 
Congress the following documents within 30 days of a re-
quest by the Congress for such documents: 
(1) All financial and accounting statements for 
the Global Fund and the Activities to Combat HIV/
AIDS Globally Fund, including administrative and 
grantee statements. 
(2) Reports provided to the Global Fund and 
the Activities to Combat HIV/AIDS Globally Fund 
by organizations contracted to audit recipients of 
funds. 
(3) Project proposals submitted by applicants 
for funding from the Global Fund and the Activities
to Combat HIV/AIDS Globally Fund, but which 
were not funded. 
(4) Progress reports submitted to the Global 
Fund and the Activities to Combat HIV/AIDS Glob-
ally Fund by grantees. 
(h) SENSE OF THE CONGRESS REGARDING ENCOUR-
AGEMENT OF PRIVATE CONTRIBUTIONS TO THE GLOBAL 
FUND.—It is the sense of the Congress that the President 
should—
(1) conduct an outreach campaign that is de-
signed to—
(A) inform the public of the existence of—
(i) the Global Fund; and 
(ii) any entity that will accept private 
contributions intended for use by the Glob-
al Fund; and 
(B) encourage private contributions to the 
Global Fund; and 
(2) encourage private contributions intended for 
use by the Global Fund by—
(A) establishing and operating an Internet 
website, and publishing information about the 
website; and 
(B) making public service announcements 
on radio and television.
SEC. 
203. 
VOLUNTARY 
CONTRIBUTIONS 
TO 
INTER-
NATIONAL VACCINE FUNDS. 
(a) VACCINE FUND.—Section 302(k) of the Foreign 
Assistance Act of 1961 (22 U.S.C. 2222(k)) is amended—
(1) by striking ‘‘$50,000,000 for each of the 
fiscal years 2001 and 2002’’ and inserting ‘‘such 
sums as may be necessary for each of the fiscal 
years 2004 through 2008’’; and 
(2) by striking ‘‘Global Alliance for Vaccines 
and Immunizations’’ and inserting ‘‘Vaccine Fund’’. 
(b) INTERNATIONAL AIDS VACCINE INITIATIVE.—
Section 302(l) of the Foreign Assistance Act of 1961 (22 
U.S.C. 2222(l)) is amended by striking ‘‘$10,000,000 for 
each of the fiscal years 2001 and 2002’’ and inserting 
‘‘such sums as may be necessary for each of the fiscal 
years 2004 through 2008’’.
(c) SUPPORT FOR THE DEVELOPMENT OF MALARIA 
VACCINE.—Section 302 of the Foreign Assistance Act of 
1961 (22 U.S.C. 2222)) is amended by adding at the end 
the following new subsection: 
‘‘(m) In addition to amounts otherwise available 
under this section, there are authorized to be appropriated 
to the President such sums as may be necessary for each 
of the fiscal years 2004 through 2008 to be available for 
United States contributions to malaria vaccine develop-
ment programs, including the Malaria Vaccine Initiative
of the Program for Appropriate Technologies in Health 
(PATH).’’. 
TITLE III—BILATERAL EFFORTS 
Subtitle A—General Assistance and 
Programs 
SEC. 301. ASSISTANCE TO COMBAT HIV/AIDS. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151 et seq.) is amended—
(1) in section 104(c) (22 U.S.C. 2151b(c)), by 
striking paragraphs (4) through (7); and 
(2) by inserting after section 104 the following 
new section: 
‘‘SEC. 104A. ASSISTANCE TO COMBAT HIV/AIDS. 
‘‘(a) FINDING.—Congress recognizes that the alarm-
ing spread of HIV/AIDS in countries in sub-Saharan Afri-
ca, the Caribbean, and other developing countries is a 
major global health, national security, development, and 
humanitarian crisis. 
‘‘(b) POLICY.—It is a major objective of the foreign 
assistance program of the United States to provide assist-
ance for the prevention, treatment, and control of HIV/
AIDS. The United States and other developed countries 
should provide assistance to countries in sub-Saharan Af-
rica, the Caribbean, and other countries and areas to con-
trol this crisis through HIV/AIDS prevention, treatment, 
monitoring, and related activities, particularly activities 
focused on women and youth, including strategies to pro-
tect women and prevent mother-to-child transmission of 
the HIV infection. 
‘‘(c) AUTHORIZATION.—
‘‘(1) IN
GENERAL.—Consistent with section 
104(c), the President is authorized to furnish assist-
ance, on such terms and conditions as the President 
may determine, for HIV/AIDS, including to prevent, 
treat, and monitor HIV/AIDS, and carry out related 
activities, in countries in sub-Saharan Africa, the 
Caribbean, and other countries and areas. 
‘‘(2) ROLE OF NGOS.—It is the sense of Con-
gress that the President should provide an appro-
priate level of assistance under paragraph (1) 
through nongovernmental organizations (including 
faith-based and community-based organizations) in 
countries in sub-Saharan Africa, the Caribbean, and 
other countries and areas affected by the HIV/AIDS 
pandemic. 
‘‘(3) 
COORDINATION
OF
ASSISTANCE
EF-
FORTS.—The President shall coordinate the provi-
sion of assistance under paragraph (1) with the pro-
vision of related assistance by the Joint United Na-
tions Programme on HIV/AIDS (UNAIDS), the 
United Nations Children’s Fund (UNICEF), the 
World Health Organization (WHO), the United Na-
tions Development Programme (UNDP), the Global 
Fund to Fight AIDS, Tuberculosis and Malaria and 
other appropriate international organizations (such 
as the International Bank for Reconstruction and 
Development), relevant regional multilateral develop-
ment institutions, national, state, and local govern-
ments of foreign countries, appropriate governmental 
and nongovernmental organizations, and relevant ex-
ecutive branch agencies. 
‘‘(d) ACTIVITIES SUPPORTED.—Assistance provided 
under subsection (c) shall, to the maximum extent prac-
ticable, be used to carry out the following activities: 
‘‘(1) PREVENTION.—Prevention of HIV/AIDS 
through activities including—
‘‘(A) programs and efforts that are de-
signed or intended to impart knowledge with 
the exclusive purpose of helping individuals 
avoid behaviors that place them at risk of HIV 
infection, including integration of such pro-
grams into health programs and the inclusion 
in counseling programs of information on meth-
ods of avoiding infection of HIV, including de-
laying sexual debut, abstinence, fidelity and mo-
nogamy, reduction of casual sexual partnering, 
reducing sexual violence and coercion, including 
child marriage, widow inheritance, and polyg-
amy, and where appropriate, use of condoms; 
‘‘(B) assistance to establish and implement 
culturally appropriate HIV/AIDS education and 
prevention programs that focus on helping indi-
viduals avoid infection of HIV/AIDS, imple-
mented through nongovernmental organizations, 
including faith-based and community-based or-
ganizations, particularly those organizations 
that utilize both professionals and volunteers 
with appropriate skills, experience, and commu-
nity presence; 
‘‘(C) assistance for the purpose of encour-
aging men to be responsible in their sexual be-
havior, child rearing, and to respect women; 
‘‘(D) assistance for the purpose of pro-
viding voluntary testing and counseling (includ-
ing the incorporation of confidentiality protec-
tions with respect to such testing and coun-
seling); 
‘‘(E) assistance for the purpose of pre-
venting mother-to-child transmission of the
HIV infection, including medications to prevent 
such transmission and access to infant formula 
and other alternatives for infant feeding; 
‘‘(F) assistance to ensure a safe blood sup-
ply and sterile medical equipment; 
‘‘(G) assistance to help avoid substance 
abuse and intravenous drug use that can lead 
to HIV infection; and 
(H) assistance for the purpose of increas-
ing women’s access to employment opportuni-
ties, income, productive resources, and micro-
finance programs, where appropriate. 
‘‘(2) TREATMENT.—The treatment and care of 
individuals with HIV/AIDS, including—
‘‘(A) assistance to establish and implement 
programs to strengthen and broaden indigenous 
health care delivery systems and the capacity of 
such systems to deliver HIV/AIDS pharma-
ceuticals and otherwise provide for the treat-
ment of individuals with HIV/AIDS, including 
clinical training for indigenous organizations 
and health care providers; 
‘‘(B) assistance to strengthen and expand 
hospice and palliative care programs to assist 
patients debilitated by HIV/AIDS, their fami-
lies, and the primary caregivers of such pa-
tients, including programs that utilize faith-
based and community-based organizations; and 
‘‘(C) assistance for the purpose of the care 
and treatment of individuals with HIV/AIDS 
through the provision of pharmaceuticals, in-
cluding antiretrovirals and other pharma-
ceuticals and therapies for the treatment of op-
portunistic infections, nutritional support, and 
other treatment modalities. 
‘‘(3) 
PREVENTATIVE
INTERVENTION
EDU-
CATION AND TECHNOLOGIES.—(A) With particular 
emphasis on specific populations that represent a 
particularly high risk of contracting or spreading 
HIV/AIDS, including those exploited through the 
sex trade, victims of rape and sexual assault, indi-
viduals already infected with HIV/AIDS, and in 
cases of occupational exposure of health care work-
ers, assistance with efforts to reduce the risk of 
HIV/AIDS infection including post-exposure phar-
maceutical prophylaxis, and necessary pharma-
ceuticals and commodities, including test kits, 
condoms, and, when proven effective, microbicides. 
‘‘(B) Bulk purchases of available test kits, 
condoms, and, when proven effective, microbicides
that are intended to reduce the risk of HIV/AIDS
transmission and for appropriate program support 
for the introduction and distribution of these com-
modities, as well as education and training on the 
use of the technologies. 
‘‘(4) MONITORING.—The monitoring of pro-
grams, projects, and activities carried out pursuant 
to paragraphs (1) through (3), including—
‘‘(A) monitoring to ensure that adequate 
controls are established and implemented to 
provide HIV/AIDS pharmaceuticals and other 
appropriate medicines to poor individuals with 
HIV/AIDS; 
‘‘(B) appropriate evaluation and surveil-
lance activities; 
‘‘(C) monitoring to ensure that appropriate 
measures are being taken to maintain the sus-
tainability of HIV/AIDS pharmaceuticals (espe-
cially antiretrovirals) and ensure that drug re-
sistance is not compromising the benefits of 
such pharmaceuticals; and 
‘‘(D) monitoring to ensure appropriate law 
enforcement officials are working to ensure that 
HIV/AIDS pharmaceuticals are not diminished
through illegal counterfeiting or black market 
sales of such pharmaceuticals. 
‘‘(5) PHARMACEUTICALS.—
‘‘(A) PROCUREMENT.—The procurement of 
HIV/AIDS pharmaceuticals, antiviral therapies, 
and other appropriate medicines, including 
medicines to treat opportunistic infections. 
‘‘(B) MECHANISMS FOR QUALITY CONTROL 
AND
SUSTAINABLE
SUPPLY.—Mechanisms to 
ensure that such HIV/AIDS pharmaceuticals, 
antiretroviral therapies, and other appropriate 
medicines are quality-controlled and sustainably 
supplied. 
‘‘(C) DISTRIBUTION.—The distribution of 
such 
HIV/AIDS 
pharmaceuticals, 
antiviral 
therapies, and other appropriate medicines (in-
cluding medicines to treat opportunistic infec-
tions) to qualified national, regional, or local or-
ganizations for the treatment of individuals 
with HIV/AIDS in accordance with appropriate 
HIV/AIDS testing and monitoring requirements 
and treatment protocols and for the prevention 
of mother-to-child transmission of the HIV in-
fection.
‘‘(6) RELATED ACTIVITIES.—The conduct of re-
lated activities, including—
‘‘(A) the care and support of children who 
are orphaned by the HIV/AIDS pandemic, in-
cluding services designed to care for orphaned 
children in a family environment which rely on 
extended family members; 
‘‘(B) improved infrastructure and institu-
tional capacity to develop and manage edu-
cation, prevention, and treatment programs, in-
cluding training and the resources to collect 
and maintain accurate HIV surveillance data to 
target programs and measure the effectiveness 
of interventions; and 
‘‘(C) vaccine research and development 
partnership programs with specific plans of ac-
tion to develop a safe, effective, accessible, pre-
ventive HIV vaccine for use throughout the 
world. 
‘‘(7) COMPREHENSIVE
HIV/AIDS
PUBLIC-PRI-
VATE PARTNERSHIPS.—The establishment and oper-
ation of public-private partnership entities within 
countries in sub-Saharan Africa, the Caribbean, and 
other countries affected by the HIV/AIDS pandemic 
that are dedicated to supporting the national strat-
egy of such countries regarding the prevention, 
treatment, and monitoring of HIV/AIDS. Each such 
public-private partnership should—
‘‘(A) support the development, implementa-
tion, and management of comprehensive HIV/
AIDS plans in support of the national HIV/
AIDS strategy; 
‘‘(B) operate at all times in a manner that 
emphasizes efficiency, accountability, and re-
sults-driven programs; 
‘‘(C) engage both local and foreign devel-
opment partners and donors, including busi-
nesses, government agencies, academic institu-
tions, nongovernmental organizations, founda-
tions, multilateral development agencies, and 
faith-based organizations, to assist the country 
in coordinating and implementing HIV/AIDS 
prevention, treatment, and monitoring pro-
grams in accordance with its national HIV/
AIDS strategy; 
‘‘(D) provide technical assistance, consult-
ant services, financial planning, monitoring and 
evaluation, and research in support of the na-
tional HIV/AIDS strategy; and
‘‘(E) establish local human resource capac-
ities for the national HIV/AIDS strategy 
through the transfer of medical, managerial, 
leadership, and technical skills. 
‘‘(e) ANNUAL REPORT.—
‘‘(1) IN GENERAL.—Not later than January 31 
of each year, the President shall submit to the Com-
mittee on Foreign Relations of the Senate and the 
Committee on International Relations of the House 
of Representatives a report on the implementation of 
this section for the prior fiscal year. 
‘‘(2) REPORT
ELEMENTS.—Each report shall 
include—
‘‘(A) a description of efforts made by each 
relevant executive branch agency to implement 
the policies set forth in this section, section 
104B, and section 104C; 
‘‘(B) a description of the programs estab-
lished pursuant to such sections; and 
‘‘(C) a detailed assessment of the impact 
of programs established pursuant to such sec-
tions, including—
‘‘(i)(I) the effectiveness of such pro-
grams in reducing the spread of the HIV 
infection, particularly in women and girls,
in reducing mother-to-child transmission of 
the HIV infection, and in reducing mor-
tality rates from HIV/AIDS; and 
‘‘(II) the number of patients currently 
receiving treatment for AIDS in each 
country that receives assistance under this 
Act. 
‘‘(ii) the progress made toward im-
proving health care delivery systems (in-
cluding the training of adequate numbers 
of staff) and infrastructure to ensure in-
creased access to care and treatment; 
‘‘(iii) with respect to tuberculosis, the 
increase in the number of people treated 
and the increase in number of tuberculosis 
patients cured through each program, 
project, or activity receiving United States 
foreign assistance for tuberculosis control 
purposes; and 
‘‘(iv) with respect to malaria, the in-
crease in the number of people treated and 
the increase in number of malaria patients 
cured through each program, project, or 
activity receiving United States foreign as-
sistance for malaria control purposes.
‘‘(f) FUNDING LIMITATION.—Of the funds made 
available to carry out this section in any fiscal year, not 
more than 7 percent may be used for the administrative 
expenses of the United States Agency for International 
Development in support of activities described in section 
104(c), this section, section 104B, and section 104C. Such 
amount shall be in addition to other amounts otherwise 
available for such purposes. 
‘‘(g) DEFINITIONS.—In this section: 
‘‘(1) AIDS.—The term ‘AIDS’ means acquired 
immune deficiency syndrome. 
‘‘(2) HIV.—The term ‘HIV’ means the human 
immunodeficiency virus, the pathogen that causes 
AIDS. 
‘‘(3) 
HIV/AIDS.—The 
term 
‘HIV/AIDS’ 
means, with respect to an individual, an individual 
who is infected with HIV or living with AIDS. 
‘‘(4) RELEVANT
EXECUTIVE
BRANCH
AGEN-
CIES.—The term ‘relevant executive branch agencies’ 
means the Department of State, the United States 
Agency for International Development, the Depart-
ment of Health and Human Services (including its 
agencies and offices), and any other department or 
agency of the United States that participates in 
international HIV/AIDS activities pursuant to the
authorities of such department or agency or this 
Act.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds avail-
able under section 104(c) of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151b(c)) for such purpose 
or under any other provision of that Act, there are 
authorized to be appropriated to the President, from 
amounts authorized to be appropriated under section 
401, such sums as may be necessary for each of the 
fiscal years 2004 through 2008 to carry out section 
104A of the Foreign Assistance Act of 1961, as 
added by subsection (a). 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended. 
(3) ALLOCATION OF FUNDS.—Of the amount 
authorized to be appropriated by paragraph (1) for 
the fiscal years 2004 through 2008, such sums as 
may be necessary are authorized to be appropriated 
to carry out section 104A(d)(4) of the Foreign As-
sistance Act of 1961 (as added by subsection (a)), 
relating to the procurement and distribution of HIV/
AIDS pharmaceuticals.
(c) RELATIONSHIP TO ASSISTANCE PROGRAMS TO 
ENHANCE NUTRITION.—In recognition of the fact that 
malnutrition may hasten the progression of HIV to AIDS 
and may exacerbate the decline among AIDS patients 
leading to a shorter life span, the Administrator of the 
United States Agency for International Development shall, 
as appropriate—
(1) integrate nutrition programs with HIV/
AIDS activities, generally; 
(2) provide, as a component of an anti-
retroviral therapy program, support for food and nu-
trition to individuals infected with and affected by 
HIV/AIDS; and 
(3) provide support for food and nutrition for 
children affected by HIV/AIDS and to communities 
and households caring for children affected by HIV/
AIDS. 
(d) ELIGIBILITY FOR ASSISTANCE.—An organization 
that is otherwise eligible to receive assistance under sec-
tion 104A of the Foreign Assistance Act of 1961 (as 
added by subsection (a)) or under any other provision of 
this Act (or any amendment made by this Act) to prevent, 
treat, or monitor HIV/AIDS shall not be required, as a 
condition of receiving the assistance, to endorse or utilize 
a multisectoral approach to combatting HIV/AIDS, or to
endorse, utilize, or participate in a prevention method or 
treatment program to which the organization has a reli-
gious or moral objection. 
(e) LIMITATION.—No funds made available to carry 
out this Act, or any amendment made by this Act, may 
be used to promote or advocate the legalization or practice 
of prostitution or sex trafficking. Nothing in the preceding 
sentence shall be construed to preclude the provision to 
individuals of palliative care, treatment, or post-exposure 
pharmaceutical prophylaxis, and necessary pharma-
ceuticals and commodities, including test kits, condoms, 
and, when proven effective, microbicides. 
(f) LIMITATION.—No funds made available to carry 
out this Act, or any amendment made by this Act, may 
be used to provide assistance to any group or organization 
that does not have a policy explicitly opposing prostitution 
and sex trafficking. 
(g) SENSE OF CONGRESS RELATING TO FOOD AS-
SISTANCE FOR INDIVIDUALS LIVING WITH HIV/AIDS.—
(1) FINDINGS.—Congress finds the following: 
(A) The United States provides more than 
60 percent of all food assistance worldwide. 
(B) According to the United Nations 
World Food Program and other United Nations 
agencies, food insecurity of individuals infected
or living with HIV/AIDS is a major problem in 
countries with large populations of such individ-
uals, particularly in African countries. 
(C) Although the United States is willing 
to provide food assistance to these countries in 
need, a few of the countries object to part or 
all of the assistance because of fears of benign 
genetic modifications to the foods. 
(D) Healthy and nutritious foods for indi-
viduals infected or living with HIV/AIDS are an 
important complement to HIV/AIDS medicines 
for such individuals. 
(E) Individuals infected with HIV have 
higher nutritional requirements than individuals 
who are not infected with HIV, particularly 
with respect to the need for protein. Also, there 
is evidence to suggest that the full benefit of 
therapy to treat HIV/AIDS may not be 
achieved in individuals who are malnourished, 
particularly in pregnant and lactating women. 
(2) SENSE OF CONGRESS.—It is therefore the 
sense of Congress that United States food assistance 
should be accepted by countries with large popu-
lations of individuals infected or living with HIV/
AIDS, particularly African countries, in order to 
help feed such individuals. 
SEC. 302. ASSISTANCE TO COMBAT TUBERCULOSIS. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151 et seq.), as amended by sec-
tion 301 of this Act, is further amended by inserting after 
section 104A the following new section: 
‘‘SEC. 104B. ASSISTANCE TO COMBAT TUBERCULOSIS. 
‘‘(a) FINDINGS.—Congress makes the following find-
ings: 
‘‘(1) Congress recognizes the growing inter-
national problem of tuberculosis and the impact its 
continued existence has on those countries that had 
previously largely controlled the disease. 
‘‘(2) Congress further recognizes that the 
means exist to control and treat tuberculosis 
through expanded use of the DOTS (Directly Ob-
served Treatment Short-course) treatment strategy, 
including DOTS-Plus to address multi-drug resist-
ant tuberculosis, and adequate investment in newly 
created mechanisms to increase access to treatment, 
including the Global Tuberculosis Drug Facility es-
tablished in 2001 pursuant to the Amsterdam Dec-
laration to Stop TB and the Global Alliance for TB 
Drug Development. 
‘‘(b) POLICY.—It is a major objective of the foreign 
assistance program of the United States to control tuber-
culosis, including the detection of at least 70 percent of 
the cases of infectious tuberculosis, and the cure of at 
least 85 percent of the cases detected, not later than De-
cember 31, 2005, in those countries classified by the 
World Health Organization as among the highest tuber-
culosis burden, and not later than December 31, 2010, 
in all countries in which the United States Agency for 
International Development has established development 
programs. 
‘‘(c) AUTHORIZATION.—To carry out this section and 
consistent with section 104(c), the President is authorized 
to furnish assistance, on such terms and conditions as the 
President may determine, for the prevention, treatment, 
control, and elimination of tuberculosis.
‘‘(d) COORDINATION.—In carrying out this section, 
the President shall coordinate with the World Health Or-
ganization, the Global Fund to Fight AIDS, Tuberculosis, 
and Malaria, and other organizations with respect to the 
development and implementation of a comprehensive tu-
berculosis control program.
‘‘(e) PRIORITY TO DOTS COVERAGE.—In furnishing 
assistance under subsection (c), the President shall give 
priority to activities that increase Directly Observed 
Treatment Short-course (DOTS) coverage and treatment 
of multi-drug resistant tuberculosis where needed using 
DOTS-Plus, including funding for the Global Tuberculosis 
Drug Facility, the Stop Tuberculosis Partnership, and the 
Global Alliance for TB Drug Development. In order to 
meet the requirement of the preceding sentence, the Presi-
dent should ensure that not less than 75 percent of the 
amount made available to carry out this section for a fiscal 
year should be expended for antituberculosis drugs, sup-
plies, direct patient services, and training in diagnosis and 
treatment for Directly Observed Treatment Short-course 
(DOTS) coverage and treatment of multi-drug resistant 
tuberculosis using DOTS-Plus, including substantially in-
creased funding for the Global Tuberculosis Drug Facility. 
‘‘(f) DEFINITIONS.—In this section: 
‘‘(1) DOTS.—The term ‘DOTS’ or ‘Directly 
Observed Treatment Short-course’ means the World 
Health 
Organization-recommended 
strategy 
for 
treating tuberculosis. 
‘‘(2) DOTS-PLUS.—The term ‘DOTS-Plus’ 
means a comprehensive tuberculosis management 
strategy that is built upon and works as a supple-
ment to the standard DOTS strategy, and which 
takes into account specific issues (such as use of sec-
ond line anti-tuberculosis drugs) that need to be ad-
dressed in areas where there is high prevalence of 
multi-drug resistant tuberculosis. 
‘‘(3) GLOBAL
ALLIANCE
FOR
TUBERCULOSIS 
DRUG
DEVELOPMENT.—The term ‘Global Alliance 
for Tuberculosis Drug Development’ means the pub-
lic-private partnership that brings together leaders 
in health, science, philanthropy, and private industry 
to devise new approaches to tuberculosis and to en-
sure that new medications are available and afford-
able in high tuberculosis burden countries and other 
affected countries. 
‘‘(4) GLOBAL
TUBERCULOSIS
DRUG
FACIL-
ITY.—The term ‘Global Tuberculosis Drug Facility 
(GDF)’ means the new initiative of the Stop Tuber-
culosis Partnership to increase access to high-quality 
tuberculosis drugs to facilitate DOTS expansion. 
‘‘(5) STOP TUBERCULOSIS PARTNERSHIP.—The 
term ‘Stop Tuberculosis Partnership’ means the 
partnership of the World Health Organization, do-
nors including the United States, high tuberculosis 
burden countries, multilateral agencies, and non-
governmental and technical agencies committed to
short- and long-term measures required to control 
and eventually eliminate tuberculosis as a public 
health problem in the world.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds avail-
able under section 104(c) of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151b(c)) for such purpose 
or under any other provision of that Act, there are 
authorized to be appropriated to the President, from 
amounts authorized to be appropriated under section 
401, such sums as may be necessary for each of the 
fiscal years 2004 through 2008 to carry out section 
104B of the Foreign Assistance Act of 1961, as 
added by subsection (a). 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to the authorization of appropria-
tions under paragraph (1) are authorized to remain 
available until expended. 
(3) TRANSFER OF PRIOR YEAR FUNDS.—Unob-
ligated balances of funds made available for fiscal 
year 2001, 2002, or 2003 under section 104(c)(7) of 
the Foreign Assistance Act of 1961 (22 U.S.C. 
2151b(c)(7) (as in effect immediately before the date 
of enactment of this Act) shall be transferred to, 
merged with, and made available for the same pur-
poses as funds made available for fiscal years 2004 
through 2008 under paragraph (1). 
SEC. 303. ASSISTANCE TO COMBAT MALARIA. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151 et seq.), as amended by sec-
tions 301 and 302 of this Act, is further amended by in-
serting after section 104B the following new section: 
‘‘SEC. 104C. ASSISTANCE TO COMBAT MALARIA. 
‘‘(a) FINDING.—Congress finds that malaria kills 
more people annually than any other communicable dis-
ease except tuberculosis, that more than 90 percent of all 
malaria cases are in sub-Saharan Africa, and that children 
and women are particularly at risk. Congress recognizes 
that there are cost-effective tools to decrease the spread 
of malaria and that malaria is a curable disease if prompt-
ly diagnosed and adequately treated. 
‘‘(b) POLICY.—It is a major objective of the foreign 
assistance program of the United States to provide assist-
ance for the prevention, control, and cure of malaria. 
‘‘(c) AUTHORIZATION.—To carry out this section and 
consistent with section 104(c), the President is authorized 
to furnish assistance, on such terms and conditions as the 
President may determine, for the prevention, treatment, 
control, and elimination of malaria.
‘‘(d) COORDINATION.—In carrying out this section, 
the President shall coordinate with the World Health Or-
ganization, the Global Fund to Fight AIDS, Tuberculosis, 
and Malaria, the Department of Health and Human Serv-
ices (the Centers for Disease Control and Prevention and 
the National Institutes of Health), and other organiza-
tions with respect to the development and implementation 
of a comprehensive malaria control program.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds avail-
able under section 104(c) of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151b(c)) for such purpose 
or under any other provision of that Act, there are 
authorized to be appropriated to the President, from 
amounts authorized to be appropriated under section 
401, such sums as may be necessary for fiscal years 
2004 through 2008 to carry out section 104C of the 
Foreign Assistance Act of 1961, as added by sub-
section (a), including for the development of anti-
malarial pharmaceuticals by the Medicines for Ma-
laria Venture. 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended.
(3) TRANSFER OF PRIOR YEAR FUNDS.—Unob-
ligated balances of funds made available for fiscal 
year 2001, 2002, or 2003 under section 104(c) of 
the Foreign Assistance Act of 1961 (22 U.S.C. 
2151b(c) (as in effect immediately before the date of 
enactment of this Act) and made available for the 
control of malaria shall be transferred to, merged 
with, and made available for the same purposes as 
funds made available for fiscal years 2004 through 
2008 under paragraph (1). 
(c) CONFORMING AMENDMENT.—Section 104(c) of 
the Foreign Assistance Act of 1961 (22 U.S.C. 2151b(c)), 
as amended by section 301 of this Act, is further amended 
by adding after paragraph (3) the following: 
‘‘(4) RELATIONSHIP TO OTHER LAWS.—Assistance 
made available under this subsection and sections 104A, 
104B, and 104C, and assistance made available under 
chapter 4 of part II to carry out the purposes of this sub-
section and the provisions cited in this paragraph, may 
be made available notwithstanding any other provision of 
law that restricts assistance to foreign countries, except 
for the provisions of this subsection, the provisions of law 
cited in this paragraph, subsection (f), section 634A of 
this Act, and provisions of law that limit assistance to or-
ganizations that support or participate in a program of
coercive abortion or involuntary sterilization included 
under the Child Survival and Health Programs Fund 
heading in the Consolidated Appropriations Resolution, 
2003 (Public Law 108–7).’’. 
SEC. 304. PILOT PROGRAM FOR THE PLACEMENT OF 
HEALTH CARE PROFESSIONALS IN OVERSEAS 
AREAS SEVERELY AFFECTED BY HIV/AIDS, 
TUBERCULOSIS, AND MALARIA. 
(a) IN GENERAL.—The President should establish a 
program to demonstrate the feasibility of facilitating the 
service of United States health care professionals in those 
areas of sub-Saharan Africa and other parts of the world 
severely affected by HIV/AIDS, tuberculosis, and malaria. 
(b) REQUIREMENTS.—Participants in the program 
shall—
(1) provide basic health care services for those 
infected and affected by HIV/AIDS, tuberculosis, 
and malaria in the area in which they are serving; 
(2) provide on-the-job training to medical and 
other personnel in the area in which they are serving 
to strengthen the basic health care system of the af-
fected countries; 
(3) provide health care educational training for 
residents of the area in which they are serving; 
(4) serve for a period of up to three years; and
(5) meet the eligibility requirements in sub-
section (d). 
(c) ELIGIBILITY REQUIREMENTS.—To be eligible to 
participate in the program, a candidate shall—
(1) be a national of the United States who is 
a trained health care professional and who meets the 
educational and licensure requirements necessary to 
be such a professional such as a physician, nurse, 
physician assistant, nurse practitioner, pharmacist, 
other type of health care professional, or other indi-
vidual determined to be appropriate by the Presi-
dent; or 
(2) be a retired commissioned officer of the 
Public Health Service Corps. 
(d) RECRUITMENT.—The President shall ensure that 
information on the program is widely distributed, includ-
ing the distribution of information to schools for health 
professionals, hospitals, clinics, and nongovernmental or-
ganizations working in the areas of international health 
and aid. 
(e) PLACEMENT OF PARTICIPANTS.—
(1) IN
GENERAL.—To the maximum extent 
practicable, participants in the program shall serve 
in the poorest areas of the affected countries, where 
health care needs are likely to be the greatest. The
decision on the placement of a participant should be 
made in consultation with relevant officials of the af-
fected country at both the national and local level as 
well as with local community leaders and organiza-
tions. 
(2) COORDINATION.—Placement of participants 
in the program shall be coordinated with the United 
States Agency for International Development in 
countries in which that Agency is conducting HIV/
AIDS, tuberculosis, or malaria programs. Overall co-
ordination of placement of participants in the pro-
gram shall be made by the Coordinator of United 
States Government Activities to Combat HIV/AIDS 
Globally (as described in section 1(f) of the State 
Department Basic Authorities Act of 1956 (as 
added by section 102(a) of this Act)). 
(f) INCENTIVES.—The President may offer such in-
centives as the President determines to be necessary to 
encourage individuals to participate in the program, such 
as partial payment of principal, interest, and related ex-
penses on government and commercial loans for edu-
cational expenses relating to professional health training 
and, where possible, deferment of repayments on such 
loans, the provision of retirement benefits that would oth-
erwise be jeopardized by participation in the program, and 
other incentives. 
(g) REPORT.—Not later than 18 months after the 
date of enactment of this Act, the President shall submit 
to the appropriate congressional committees a report on 
steps taken to establish the program, including—
(1) the process of recruitment, including the 
venues for recruitment, the number of candidates re-
cruited, the incentives offered, if any, and the cost 
of those incentives; 
(2) the process, including the criteria used, for 
the selection of participants; 
(3) the number of participants placed, the coun-
tries in which they were placed, and why those coun-
tries were selected; and 
(4) the potential for expansion of the program.
(h) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to amounts oth-
erwise available for such purpose, there are author-
ized to be appropriated to the President, from 
amounts authorized to be appropriated under section 
401, such sums as may be necessary for each of the 
fiscal years 2004 through 2008 to carry out the pro-
gram.
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to the authorization of appropria-
tions under paragraph (1) are authorized to remain 
available until expended. 
SEC. 305. REPORT ON TREATMENT ACTIVITIES BY REL-
EVANT EXECUTIVE BRANCH AGENCIES. 
(a) IN GENERAL.—Not later than 15 months after 
the date of enactment of this Act, the President shall sub-
mit to appropriate congressional committees a report on 
the programs and activities of the relevant executive 
branch agencies that are directed to the treatment of indi-
viduals in foreign countries infected with HIV or living 
with AIDS. 
(b) REPORT ELEMENTS.—The report shall include—
(1) a description of the activities of relevant ex-
ecutive branch agencies with respect to—
(A) the treatment of opportunistic infec-
tions; 
(B) the use of antiretrovirals; 
(C) the status of research into successful 
treatment protocols for individuals in the devel-
oping world; 
(D) technical assistance and training of 
local health care workers (in countries affected 
by the pandemic) to administer antiretrovirals,
manage side effects, and monitor patients’ viral 
loads and immune status; 
(E) the status of strategies to promote 
sustainability of HIV/AIDS pharmaceuticals 
(including antiretrovirals) and the effects of 
drug resistance on HIV/AIDS patients; and 
(F) the status of appropriate law enforce-
ment officials working to ensure that HIV/
AIDS pharmaceutical treatment is not dimin-
ished through illegal counterfeiting and black 
market sales of such pharmaceuticals; 
(2) information on existing pilot projects, in-
cluding a discussion of why a given population was 
selected, the number of people treated, the cost of 
treatment, the mechanisms established to ensure 
that treatment is being administered effectively and 
safely, and plans for scaling up pilot projects (in-
cluding projected timelines and required resources); 
and 
(3) an explanation of how those activities relate 
to efforts to prevent the transmission of the HIV in-
fection.
SEC. 306. STRATEGIES TO IMPROVE INJECTION SAFETY. 
Section 307 of the Public Health Service Act (42 
U.S.C. 242l) is amended by adding at the end the fol-
lowing: 
‘‘(d) In carrying out immunization programs and 
other programs in developing countries for the prevention, 
treatment, and control of infectious diseases, including 
HIV/AIDS, tuberculosis, and malaria, the Director of the 
Centers for Disease Control and Prevention, in coordina-
tion with the Coordinator of United States Government 
Activities to Combat HIV/AIDS Globally, the National In-
stitutes of Health, national and local government, and 
other organizations, such as the World Health Organiza-
tion and the United Nations Children’s Fund, shall de-
velop and implement effective strategies to improve injec-
tion safety, including eliminating unnecessary injections, 
promoting sterile injection practices and technologies, 
strengthening the procedures for proper needle and sy-
ringe disposal, and improving the education and informa-
tion provided to the public and to health professionals.’’. 
SEC. 307. STUDY ON ILLEGAL DIVERSIONS OF PRESCRIP-
TION DRUGS. 
Not later than 180 days after enactment of this Act, 
the Secretary of Health and Human Services, in coordina-
tion with other agencies, shall submit a report to the Con-
gress that includes the following:
(1) A thorough accounting of evidence indi-
cating illegal diversion into the United States of pre-
scription drugs donated or sold for humanitarian ef-
forts, and an estimate of the extent of such diver-
sion. 
(2) Recommendations to increase the adminis-
trative and enforcement powers of the United States 
to identify, monitor, and prevent the illegal diversion 
into the United States of prescription drugs donated 
or sold for humanitarian efforts. 
(3) Recommendations and guidelines to advise 
and provide technical assistance to developing coun-
tries on how to implement a program that minimizes 
diversion into the United States of prescription 
drugs donated or sold for humanitarian efforts. 
Subtitle B—Assistance for Children 
and Families 
SEC. 311. FINDINGS. 
Congress makes the following findings: 
(1) Approximately 2,000 children around the 
world are infected each day with HIV through moth-
er-to-child transmission. Transmission can occur 
during pregnancy, labor, and delivery or through 
breast feeding. Over ninety percent of these cases
are in developing nations with little or no access to 
public health facilities. 
(2) Mother-to-child transmission is largely pre-
ventable with the proper application of pharma-
ceuticals, therapies, and other public health interven-
tions. 
(3) Certain antiretroviral drugs reduce mother-
to-child transmission by nearly 50 percent. Universal 
availability of this drug could prevent up to 400,000 
infections per year and dramatically reduce the num-
ber of AIDS-related deaths. 
(4) At the United Nations Special Session on 
HIV/AIDS in June 2001, the United States com-
mitted to the specific goals with respect to the pre-
vention of mother-to-child transmission, including 
the goals of reducing the proportion of infants in-
fected with HIV by 20 percent by the year 2005 and 
by 50 percent by the year 2010, as specified in the 
Declaration of Commitment on HIV/AIDS adopted 
by the United Nations General Assembly at the Spe-
cial Session. 
(5) Several United States Government agencies 
including the United States Agency for International 
Development and the Centers for Disease Control 
are already supporting programs to prevent mother-
to-child transmission in resource-poor nations and 
have the capacity to expand these programs rapidly 
by working closely with foreign governments and 
nongovernmental organizations. 
(6) Efforts to prevent mother-to-child trans-
mission can provide the basis for a broader response 
that includes care and treatment of mothers, fa-
thers, and other family members who are infected 
with HIV or living with AIDS. 
(7) HIV/AIDS has devastated the lives of 
countless children and families across the globe. 
Since the epidemic began, an estimated 13,200,000 
children under the age of 15 have been orphaned by 
AIDS, that is they have lost their mother or both 
parents to the disease. The Joint United Nations 
Program on HIV/AIDS (UNAIDS) estimates that 
this number will double by the year 2010. 
(8) HIV/AIDS also targets young people be-
tween the ages of 15 to 24, particularly young 
women, many of whom carry the burden of caring 
for family members living with HIV/AIDS. An esti-
mated 10,300,000 young people are now living with 
HIV/AIDS. One-half of all new infections are occur-
ring among this age group.
SEC. 312. POLICY AND REQUIREMENTS. 
(a) POLICY.—The United States Government’s re-
sponse to the global HIV/AIDS pandemic should place 
high priority on the prevention of mother-to-child trans-
mission, the care and treatment of family members and 
caregivers, and the care of children orphaned by AIDS. 
To the maximum extent possible, the United States Gov-
ernment should seek to leverage its funds by seeking 
matching contributions from the private sector, other na-
tional governments, and international organizations. 
(b) REQUIREMENTS.—The 5-year United States Gov-
ernment strategy required by section 101 of this Act 
shall—
(1) provide for meeting or exceeding the goal to 
reduce the rate of mother-to-child transmission of
HIV by 20 percent by 2005 and by 50 percent by 
2010; 
(2) include programs to make available testing 
and treatment to HIV-positive women and their 
family members, including drug treatment and 
therapies to prevent mother-to-child transmission; 
and 
(3) expand programs designed to care for chil-
dren orphaned by AIDS.
SEC. 313. ANNUAL REPORTS ON PREVENTION OF MOTHER-
TO-CHILD TRANSMISSION OF THE HIV INFEC-
TION. 
(a) IN GENERAL.—Not later than one year after the 
date of the enactment of this Act, and annually thereafter 
for a period of five years, the President shall submit to 
appropriate congressional committees a report on the ac-
tivities of relevant executive branch agencies during the 
reporting period to assist in the prevention of mother-to-
child transmission of the HIV infection. 
(b) REPORT ELEMENTS.—Each report shall in-
clude—
(1) a statement of whether or not all relevant 
executive branch agencies have met the goal de-
scribed in section 312(b)(1); and 
(2) a description of efforts made by the relevant 
executive branch agencies to expand those activities, 
including—
(A) information on the number of sites 
supported for the prevention of mother-to-child 
transmission of the HIV infection; 
(B) the specific activities supported; 
(C) the number of women tested and coun-
seled; and 
(D) the number of women receiving pre-
ventative drug therapies.
(c) REPORTING PERIOD DEFINED.—In this section, 
the term ‘‘reporting period’’ means, in the case of the ini-
tial report, the period since the date of enactment of this 
Act and, in the case of any subsequent report, the period 
since the date of submission of the most recent report. 
SEC. 314. PILOT PROGRAM OF ASSISTANCE FOR CHILDREN 
AND FAMILIES AFFECTED BY HIV/AIDS. 
(a) IN GENERAL.—The President, acting through the 
United States Agency for International Development, 
should establish a program of assistance that would dem-
onstrate the feasibility of the provision of care and treat-
ment to orphans and other children and young people af-
fected by HIV/AIDS in foreign countries. 
(b) 
PROGRAM
REQUIREMENTS.—The 
program 
should—
(1) build upon and be integrated into programs 
administered as of the date of enactment of this Act 
by the relevant executive branch agencies for chil-
dren affected by HIV/AIDS; 
(2) work in conjunction with indigenous com-
munity-based programs and activities, particularly 
those that offer proven services for children; 
(3) reduce the stigma of HIV/AIDS to encour-
age vulnerable children infected with HIV or living 
with AIDS and their family members and caregivers
to avail themselves of voluntary counseling and test-
ing, and related programs, including treatments; 
(4) ensure the importance of inheritance rights 
of women, particularly women in African countries, 
due to the exponential growth in the number of 
young widows, orphaned girls, and grandmothers be-
coming heads of households as a result of the HIV/
AIDS pandemic; 
(5) provide, in conjunction with other relevant 
executive branch agencies, the range of services for 
the care and treatment, including the provision of 
antiretrovirals and other necessary pharmaceuticals, 
of children, parents, and caregivers infected with 
HIV or living with AIDS; 
(6) provide nutritional support and food secu-
rity, and the improvement of overall family health; 
(7) work with parents, caregivers, and commu-
nity-based organizations to provide children with 
educational opportunities; and 
(8) provide appropriate counseling and legal as-
sistance for the appointment of guardians and the 
handling of other issues relating to the protection of 
children. 
(c) REPORT.—Not later than 18 months after the 
date of enactment of this Act, the President should submit
a report on the implementation of this section to the ap-
propriate congressional committees. Such report should 
include a description of activities undertaken to carry out 
subsection (b)(4). 
(d) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to amounts oth-
erwise available for such purpose, there are author-
ized to be appropriated to the President, from 
amounts authorized to be appropriated under section 
401, such sums as may be necessary for each of the 
fiscal years 2004 through 2008 to carry out the pro-
gram. A significant percentage of the amount appro-
priated pursuant to the authorization of appropria-
tions under the preceding sentence for a fiscal year 
should be made available to carry out subsection 
(b)(4). 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended. 
SEC. 315. PILOT PROGRAM ON FAMILY SURVIVAL PART-
NERSHIPS. 
(a) PURPOSE.—The purpose of this section is to au-
thorize the President to establish a program, through a 
public-private partnership, for the provision of medical 
care and support services to HIV positive parents and
their children identified through existing programs to pre-
vent mother-to-child transmission of HIV in countries 
with or at risk for severe HIV epidemic with particular 
attention to resource constrained countries. 
(b) GRANTS.—
(1) IN GENERAL.—The President is authorized 
to establish a program for the award of grants to el-
igible administrative organizations to enable such or-
ganizations to award subgrants to eligible entities to 
expand activities to prevent the mother-to-child 
transmission of HIV by providing medical care and 
support services to HIV infected parents and their 
children. 
(2) USE OF FUNDS.—Amounts provided under 
a grant awarded under paragraph (1) shall be 
used—
(A) to award subgrants to eligible entities 
to enable such entities to carry out activities de-
scribed in subsection (c); 
(B) 
for 
administrative 
support 
and 
subgrant management; 
(C) for administrative data collection and 
reporting concerning grant activities; 
(D) for the monitoring and evaluation of 
grant activities;
(E) for training and technical assistance 
for subgrantees; and 
(F) to promote sustainability. 
(c) SUBGRANTS.—
(1) IN GENERAL.—An organization awarded a 
grant under subsection (b) shall use amounts re-
ceived under the grant to award subgrants to eligible 
entities. 
(2) ELIGIBILITY.—To be eligible to receive a 
subgrant under paragraph (1), an entity shall—
(A) be a local health organization, an 
international organization, or a partnership of 
such organizations; and 
(B) demonstrate to the awarding organiza-
tion that such entity—
(i) is currently administering a proven 
intervention to prevent mother-to-child 
transmission of HIV in countries with or 
at risk for severe HIV epidemic with par-
ticular attention to resource constrained 
countries, as determined by the President; 
(ii) has demonstrated support for the 
proposed program from relevant govern-
ment entities; and
(iii) is able to provide HIV care, in-
cluding 
antiretroviral 
treatment 
when 
medically 
indicated, 
to 
HIV 
positive 
women, men, and children with the support 
of the project funding. 
(3) LOCAL HEALTH AND INTERNATIONAL OR-
GANIZATIONS.—For purposes of paragraph (2)(A)—
(A) the term ‘‘local health organization’’ 
means a public sector health system, non-
governmental organization, institution of higher 
education, community-based organization, or 
nonprofit health system that provides directly, 
or has a clear link with a provider for the indi-
rect provision of, primary health care services; 
and 
(B) the term ‘‘international organization’’ 
means—
(i) a nonprofit international entity; 
(ii) an international charitable institu-
tion; 
(iii) a private voluntary international 
entity; or 
(iv) a multilateral institution. 
(4) PRIORITY
REQUIREMENT.—In awarding 
subgrants under this subsection, the organization
shall give priority to eligible applicants that are cur-
rently administering a program of proven interven-
tion to HIV positive individuals to prevent mother-
to-child transmission in countries with or at risk for 
severe HIV epidemic with particular attention to re-
source constrained countries, and who are currently 
administering a program to HIV positive women, 
men, and children to provide life-long care in family-
centered care programs using non-Federal funds. 
(5) SELECTION OF SUBGRANT RECIPIENTS.—In 
awarding subgrants under this subsection, the orga-
nization should—
(A) consider applicants from a range of 
health care settings, program approaches, and 
geographic locations; and 
(B) if appropriate, award not less than 1 
grant to an applicant to fund a national system 
of health care delivery to HIV positive families. 
(6) USE OF SUBGRANT FUNDS.—An eligible en-
tity awarded a subgrant under this subsection shall 
use subgrant funds to expand activities to prevent 
mother-to-child transmission of HIV by providing 
medical treatment and care and support services to 
parents and their children, which may include—
(A) providing treatment and therapy, when 
medically indicated, to HIV-infected women, 
their children, and families; 
(B) the hiring and training of local per-
sonnel, including physicians, nurses, other 
health care providers, counselors, social work-
ers, outreach personnel, laboratory technicians, 
data managers, and administrative support per-
sonnel; 
(C) paying laboratory costs, including costs 
related to necessary equipment and diagnostic 
testing and monitoring (including rapid test-
ing), complete blood counts, standard chem-
istries, and liver function testing for infants, 
children, and parents, and costs related to the 
purchase of necessary laboratory equipment; 
(D) purchasing pharmaceuticals for HIV-
related 
conditions, 
including 
antiretroviral 
therapies; 
(E) funding support services, including ad-
herence and psychosocial support services; 
(F) operational support activities; and 
(G) conducting community outreach and 
capacity building activities, including activities 
to raise the awareness of individuals of the pro-